NTRA Stock – Exploring Recent Surge and Future Potential

Natera stock is trading -6.7% below its average target price of $103.94 after marking a 3.5% during today's morning session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $37.0 to $135.0 per share.

The stock has an average amount of shares sold short at 5.0%, and a short ratio of 3.97. The company's insiders own 3.45% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 95.2% of Natera's shares being owned by this investor type.

Institutions Invested in Natera

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 9% 10,971,895 $1,064,054,413
2023-12-31 JP Morgan Chase & Company 7% 7,954,212 $771,399,506
2023-12-31 Fred Alger Management, LLC 6% 7,076,651 $686,293,637
2023-12-31 Blackrock Inc. 5% 6,305,838 $611,540,190
2023-12-31 Samlyn Capital, LLC 3% 3,874,801 $375,778,213
2023-12-31 Farallon Capital Management LLC 3% 3,474,883 $336,994,165
2023-12-31 State Street Corporation 3% 3,185,683 $308,947,548
2023-12-31 Alliancebernstein L.P. 2% 2,990,416 $290,010,553
2023-12-31 Invesco Ltd. 2% 2,816,142 $273,109,460
2023-12-31 RTW Investments LP 2% 2,593,323 $251,500,473

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Natera.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS